당단백질 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the glycoprotein market size is expected to grow from USD 0.65 billion in 2025 to USD 0.67 billion in 2026 and is forecast to reach USD 0.81 billion by 2031 at 3.75% CAGR over 2026-2031.

This report is Segmented by Product Type (Recombinant, Native, Synthetic and Semi-Synthetic), Glycosylation Type (N-Linked, O-Linked, Mixed and Rare), Application (Therapeutics, Diagnostics, Drug Discovery and Research), End User (Pharma/Biotech, Academic Institutes, CROs/CDMOs, Hospitals), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Glycoprotein Market Trends and Insights

Expanding mAb, Fc-fusion, and Vaccine Glycoprotein Demand Fuels Near-term Growth

Monoclonal antibodies, Fc-fusion proteins, vaccines, and glycan-directed antibody-drug conjugates are driving demand in the glycoprotein market. These formats rely on stringent glycan structure control during development and release testing. Fc-glycan-specific antibody-drug conjugates are advancing in clinical trials, with candidates like JSKN003 and IBI343 showcasing the progress of glycan-linked targeting beyond discovery stages. This therapeutic momentum boosts demand for engineered upstream inputs, purification workflows, and downstream characterization services, broadening the market's revenue base.

Rising Chronic-disease Burden Accelerates Glycoprotein Therapeutic and Biomarker Adoption

The increasing prevalence of chronic and non-communicable diseases is amplifying demand for glycoprotein-based therapies, including enzyme replacement products, glycoprotein hormone analogs, and immune-targeting biologics, all dependent on specific glycan profiles for optimal function. Diagnostics are also gaining importance as glycoprotein alterations are recognized as significant disease indicators. A preclinical DGlyTAC study highlighted anti-tumor effects from removing N-glycans from PD-L1, suggesting a novel treatment approach distinct from traditional checkpoint inhibition. Such findings enhance the market's commercial potential, expanding beyond reference biologics replacement to new oncology programs targeting larger patient demographics.

High Production and Purification Costs Constrain Market Expansion

Production costs pose a significant challenge in the glycoprotein market, particularly for companies in price-sensitive environments or those scaling new programs without substantial financial backing. A study by Sartorius and Sanofi highlighted that membrane-based downstream processing costs EUR 35 per gram (USD 40.60) compared to EUR 65 per gram (USD 75.39) for resin-based chromatography, with a 29-fold throughput improvement. However, adoption remains concentrated in larger, well-funded facilities. Regulatory requirements further escalate costs, as ICH-aligned practices and FDA guidelines demand extensive characterization packages covering glycan structure, comparability, and process consistency during scale-up. These costs disproportionately impact smaller biosimilar developers and emerging-market CDMOs, slowing capacity expansion despite favorable demand conditions.

Other drivers and restraints analyzed in the detailed report include:

1. Advances in Glycoengineering and High-resolution Glycan Analytics Reshape the Production Frontier
2. Precision-medicine Biomarker Discovery in Glycoproteomics Unlocks Long-term Diagnostic Revenue
3. Glycosylation Heterogeneity Complicates Biosimilar Development and Approval

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, recombinant glycoproteins held 45.60% of the glycoprotein market share, driven by established CHO-cell infrastructure and the reliance of most approved biologics on recombinant production routes. Native glycoproteins remain relevant in analytical standards and early research but have a smaller and fragmented demand base compared to recombinant formats. Recombinant products dominate near-term revenue, particularly in regulated therapeutic manufacturing, which requires repeat purchasing and qualification work.

Synthetic and semi-synthetic glycoproteins are projected to grow at a 4.10% CAGR from 2026 to 2031, making them the fastest-growing product type. Advancements in glycoengineering, such as the use of DmPglB in E. coli and plant N-glycan remodeling, are reducing reliance on capital-intensive mammalian systems and diversifying the production base.

N-linked glycoproteins accounted for 48.75% of the market share in 2025, driven by their critical role in IgG monoclonal antibodies for function, release testing, and comparability assessments. Their dominance is reinforced by their inclusion in quality documentation for numerous marketed biologics and regulatory submissions.

O-linked glycoproteins are expected to grow at a 4.45% CAGR from 2026 to 2031, making them the fastest-growing glycosylation class. Laboratories are increasingly adopting workflows that map post-translational modifications beyond N-glycan profiles, driving demand for instruments and software capable of characterizing multiple glycan classes in regulated workflows.

Geography Analysis

In 2025, North America accounted for 41.61% of the glycoprotein market, driven by strong biologics manufacturing, a significant CRO presence, and a large base of analytical instrument suppliers. The FDA's biosimilar comparability guidance mandates glycan assessments using at least 10 reference product lots, making glycan analytics infrastructure a critical investment. In 2026, Thermo Fisher validated continuous Raman process analytical technology in monoclonal antibody bioreactors, achieving a 10% titer increase and a 60% reduction in glycation. These advancements highlight North America's leadership, supported by product demand and advanced manufacturing capabilities.

Asia-Pacific is projected to grow at a 4.20% CAGR from 2026 to 2031, making it the fastest-growing region in the glycoprotein market. Sartorius reported a 9.0% growth in bioprocess revenue in Asia/Pacific in 2025, reflecting increased investment in equipment and process infrastructure. This growth indicates the region's shift toward a broader manufacturing and analytics base, beyond low-cost production.

In 2025, Europe, the Middle East and Africa, and South America collectively held the remaining glycoprotein market share, with Europe leading due to its established biosimilar and analytical compliance ecosystem. Europe's expertise in comparability and glycan fingerprinting ensures steady demand across development and lifecycle management. The Middle East and Africa are in early development stages, with selective healthcare investments supporting diagnostic and specialty biologics capabilities. South America is also in its early stages, with academic and public research initiatives building a foundation for future glycoproteomics and biosimilar activities.

1. Abcam
2. Acro Biosystems
3. Agilent Technologies
4. Bio-Rad Laboratories
5. Bio-Techne
6. Bruker
7. CD BioGlyco
8. Creative Biolabs
9. Creative Diagnostics
10. Danaher
11. Genscript
12. Merck
13. Polysciences, Inc.
14. Promega
15. Revvity
16. Sartorius
17. Shimadzu
18. Takara Bio
19. Thermo Fisher Scientific
20. Waters Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expanding mAb, Fc-Fusion, and Vaccine Glycoprotein Demand
  • 4.2.2 Rising Chronic-Disease Demand for Glycoprotein Therapeutics and Biomarkers
  • 4.2.3 Advances in Glycoengineering and High-Resolution Glycan Analytics
  • 4.2.4 Precision-Medicine Biomarker Discovery in Glycoproteomics
  • 4.2.5 Adoption of Real-Time Glycosylation PAT and MAM Workflows
  • 4.2.6 Commercialization of Glycoproteomic Liquid-Biopsy Assays
• 4.3 Market Restraints
  • 4.3.1 High Production and Purification Cost
  • 4.3.2 Glycosylation Heterogeneity and Reproducibility Complexity
  • 4.3.3 Stricter Biosimilar Comparability and Glycan Characterization Burden
  • 4.3.4 Limited Glycan Reference Standards and Cross-Lab Harmonization
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Recombinant Glycoproteins
  • 5.1.2 Native Glycoproteins
  • 5.1.3 Synthetic and Semi-synthetic Glycoproteins
• 5.2 By Glycosylation Type
  • 5.2.1 N-linked Glycoproteins
  • 5.2.2 O-linked Glycoproteins
  • 5.2.3 Mixed and Rare Glycosylation Types
• 5.3 By Application
  • 5.3.1 Therapeutics
  • 5.3.2 Diagnostics
  • 5.3.3 Drug Discovery and Research
• 5.4 By End User
  • 5.4.1 Pharmaceutical and Biotechnology Companies
  • 5.4.2 Academic and Research Institutes
  • 5.4.3 CROs and CDMOs
  • 5.4.4 Hospitals and Diagnostic Laboratories
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abcam plc
  • 6.3.2 ACROBiosystems
  • 6.3.3 Agilent Technologies
  • 6.3.4 Bio-Rad Laboratories
  • 6.3.5 Bio-Techne Corporation
  • 6.3.6 Bruker Corporation
  • 6.3.7 CD BioGlyco
  • 6.3.8 Creative Biolabs
  • 6.3.9 Creative Diagnostics
  • 6.3.10 Danaher Corporation (Cytiva)
  • 6.3.11 GenScript Biotech Corporation
  • 6.3.12 Merck KGaA
  • 6.3.13 Polysciences, Inc.
  • 6.3.14 Promega Corporation
  • 6.3.15 Revvity
  • 6.3.16 Sartorius AG
  • 6.3.17 Shimadzu Corporation
  • 6.3.18 Takara Bio Inc.
  • 6.3.19 Thermo Fisher Scientific Inc.
  • 6.3.20 Waters Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment